This is a two-arm, multi-national, multi-center, single-blind, randomized, placebo-controlled phase IIa study. A total of 30 subjects with post-COVID will be enrolled.
RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.